SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

GALAFOLD

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval August 2018).
Why 4/10
Galafold is already FDA-approved (August 2018) and commercially marketed with no pending PDUFA or pivotal readout. The next potential catalyst is the Phase 3b pediatric trial (NCT06904261) in children aged 2-12, but that is likely 12+ months from completion. As an approved drug within a diversified portfolio, impactScore is capped at 4 per the rubric.
Actionable Insight NEUTRAL

Galafold has no near-term binary catalyst; the next event to watch is the ongoing Phase 3b pediatric trial (NCT06904261), which could support a label expansion to children aged 2-12, but that readout is likely 12+ months away. For BMRN stock, the next catalysts are broader: Q4 2026 earnings (February 2027) and progress of the newly licensed Fabry ERT (HM15421/GC1134A) into the clinic.

Price Chart

Loading chart...

Executive Summary

GALAFOLD (migalastat) is an oral pharmacological chaperone for Fabry disease, a rare genetic disorder. Originally developed and marketed by Amicus Therapeutics, it was acquired by BioMarin Pharmaceutical (BMRN) in April 2026 as part of a $4.8 billion all-cash deal. FDA-approved since August 2018, Galafold is the only oral monotherapy for Fabry disease, competing against IV enzyme replacement therapies. It generated $521.7 million in 2025 revenue (up 14% YoY) and contributed $152 million in Q3 2026, BioMarin's first full quarter of ownership. The drug has strong patent protection through 2037-2042. For a non-medical investor, Galafold is a growing commercial asset within BioMarin's diversified rare-disease portfolio, but it has no near-term binary catalyst, making it a neutral watch item rather than a standalone trading driver.

How It Works

Galafold is an oral pharmacological chaperone for Fabry disease, a rare genetic disorder where patients lack a working version of an enzyme called alpha-galactosidase A. This enzyme normally breaks down a fatty substance called globotriaosylceramide (Gb3). Galafold works by binding to the patient's own defective enzyme and stabilizing it, helping it fold into the right shape so it can travel to the lysosome (the cell's recycling center) and break down Gb3. It is taken as a capsule every other day, unlike the standard IV infusions that require a hospital visit every two weeks.

Trial Status

Galafold is FDA-approved for adults with Fabry disease and amenable GLA gene variants. A Phase 3b open-label pediatric trial (NCT06904261) is ongoing, evaluating migalastat in children aged 2 to under 12 years. The study is active but not yet recruiting per ClinicalTrials.gov records.

The Two-Sided Case

▲ Bull Case5
Galafold is the only oral monotherapy for Fabry disease, offering a convenience advantage over IV enzyme replacement therapies that require bi-weekly infusions.
Revenue is growing: $521.7M in full-year 2025 (up 14% YoY) and $152M in Q3 2026 alone (first full quarter under BioMarin), contributing to BioMarin's record $1.025B quarterly revenue.
Strong patent protection with 66 US patents and estimated generic entry not until 2037-2042, providing long commercial exclusivity.
BioMarin is building a comprehensive Fabry franchise: Galafold for amenable patients plus a newly licensed next-generation long-acting subcutaneous ERT (HM15421/GC1134A) for non-amenable patients, with a $70M upfront / up to $475M deal signed October 2026.
Analyst consensus is bullish: 27 analysts cover BMRN with a mean price target of $91.56 (57% implied upside from $58.16), with 10 strong buy and 17 buy ratings vs 0 sell.
▼ Bear Case4
Galafold faces competition from established IV enzyme replacement therapies (Sanofi's Fabrazyme, Takeda's Replagal, Chiesi's Elfabrio) and emerging gene therapies and substrate reduction therapies in the Fabry pipeline.
The drug is only effective for patients with amenable GLA gene variants, which limits its addressable patient population to roughly 35-50% of Fabry patients.
Patent challenges from Teva (settled for 2037 entry) and Aurobindo create long-term generic overhang, though near-term risk is low.
BioMarin's elevated short-sale volume (59.8% of recent sessions vs 54% baseline, z-score 1.63) and several large institutional exits in Q2 2026 (Citadel near-exit, Point72 exit, Wellington exit) signal mixed sentiment around the post-Amics integration.

Upcoming Catalysts

  • Phase 3b pediatric trial (NCT06904261) readout for children aged 2-12, likely 12+ months away
  • Potential label expansion to pediatric population if trial succeeds
  • Quarterly earnings reports where Galafold revenue contribution is reported (next: Q4 2026, expected February 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 fda.gov3 biomarin.com4 biomarin.com5 biomarin.com6 biospace.com7 clinicaltrials.gov8 pharsight.greyb.com9 drugpatentwatch.com10 accessdata.fda.gov11 investors.biomarin.com12 zacks.com